TrialThe oncologist2019

Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.

Rui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.